Liu Rongqiang, Zhao Kailiang, Wang Kunpeng, Zhang Lilong, Ma Wangbin, Qiu Zhengdong, Wang Weixing
Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Front Oncol. 2023 Mar 3;13:1081655. doi: 10.3389/fonc.2023.1081655. eCollection 2023.
Many reports have described that abnormal nectin-4 expression may be used as a prognostic marker in many tumors. However, these studies failed to reach a consensus. Here, we performed a meta-analysis to comprehensively evaluate the prognostic value of nectin-4 in cancers.
Relevant studies were identified through a comprehensive search of PubMed, EMBASE and Web of science until August 31, 2022. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were used to evaluate the relationship between nectin-4 expression and overall survival (OS) and disease-free survival/progression-free survival/relapse-free survival (DFS/PFS/RFS). Odds ratios (ORs) with 95% CIs were applied to assess the relationship between nectin-4 expression and clinicopathologic features. Subgroup analysis was performed to explore the sources of heterogeneity. Sensitivity analysis and funnel plot were used to test the reliability of the results. All data analyses were performed using STATA version 12.0 software.
Fifteen articles involving 2245 patients were included in the meta-analysis. The pooled analysis showed that high nectin-4 expression was significantly associated with poor OS (HR: 1.75, 95% CI: 1.35-2.28). There was no relationship between high nectin-4 expression and DFS/PFS/RFS (HR: 178, 95% CI: 0.78-4.08).Subgroup analyses revealed that that high nectin-4 expression mainly presented adverse OS in esophageal cancer (EC) (HR: 1.78, 95% CI: 1.30-2.44) and gastric cancer (GC) (HR: 1.92, 95% CI: 1.43-2.58). We also found that high nectin-4 expression was associated with tumor diameter (big vs small) (OR: 1.96, 95% CI: 1.02-3.75), tumor stage (III-IV vs I-II) (OR: 2.04, 95% CI: 1.01-4.12) and invasion depth (T3+T4 vs T2+T1) (OR: 3.95, 95% CI: 2.06-7.57).
Nectin-4 can be used as an effective prognostic indicator for specific cancers.
许多报告描述了异常的nectin-4表达可能用作多种肿瘤的预后标志物。然而，这些研究未能达成共识。在此，我们进行了一项荟萃分析，以全面评估nectin-4在癌症中的预后价值。
通过全面检索PubMed、EMBASE和Web of science直至2022年8月31日来确定相关研究。采用合并风险比（HRs）及95%置信区间（CIs）来评估nectin-4表达与总生存期（OS）以及无病生存期/无进展生存期/无复发生存期（DFS/PFS/RFS）之间的关系。应用具有95%CI的比值比（ORs）来评估nectin-4表达与临床病理特征之间的关系。进行亚组分析以探索异质性来源。采用敏感性分析和漏斗图来检验结果的可靠性。所有数据分析均使用STATA 12.0软件进行。
荟萃分析纳入了15篇涉及2245例患者的文章。汇总分析表明，高nectin-4表达与较差的OS显著相关（HR：1.75，95%CI：1.35 - 2.28）。高nectin-4表达与DFS/PFS/RFS之间无相关性（HR：1.78，95%CI：0.78 - 4.08）。亚组分析显示，高nectin-4表达主要在食管癌（EC）（HR：1.78，95%CI：1.30 - 2.44）和胃癌（GC）（HR：1.92，95%CI：1.
